BIOCORP (FR0012788065 – ALCOR / PEA‐PME eligible) (Paris:ALCOR),
a French company specializing in the development and manufacturing of
medical devices and smart drug delivery systems, today announces the
launch of Inspair, the smart sensor which converts inhalers into
connected devices to help patients with Asthma or COPD.
“Biocorp’s objective is to develop innovative solutions in order to
improve treatment compliance by patients suffering from chronic diseases.
Significant applications have been developed in diabetology,
endocrinology and neurology with the Datapen and Easylog devices, and
our new sensor Inspair also positions us in the area of chronic lung
diseases which affect an increasing number of people in need of new
solutions to improve compliance”, said Jacques Gardette, Biocorp’s
Founder and CEO
Asthma is a chronic disease which affects the respiratory tracts: it is
characterized by an inflammation and irritation of the bronchial tubes
which overreact to various triggers, and causes attacks with typical
identifiable symptoms: difficulty in breathing, shortness of breath, dry
cough or wheezing.
Asthma is a disease lived by 4 million people in France and 334 million
in the world1, and which can rapidly affect the patients’
daily lives if it is not carefully controlled. The compliance and
monitoring of the disease are all the more necessary in that a poor
management of asthma can rapidly lead to severe asthma responsible for
more than 500,000 emergency hospitalization and 1,000 to 1,500 deaths
every year in France2. The French health insurance estimates
that nearly six in ten people with asthma have inadequate control of
their disease and treatment3.
COPD is a chronic lung disease which develops slowly and is
characterized by an airway obstruction. It is different from Asthma and
usually affects older people suffering from prolonged intoxication,
mostly because of smoking (90%). COPD affects about 3 million people in
France, and is responsible for more deaths than HIV or Influenza4.
A fastidious treatment follow-up with inhaler and/or bronchodilator
medication is thus required to reduce symptoms and improve the patient’s
quality of life.
Inspair brings an innovative and effective response to the needs of
these two pathologies: it acts directly on the treatment compliance and
also strengthens the connection between the patient and the medical
staff who can provide a real-time therapeutic follow-up. Inspair is a
smart sensor capable of converting any pressurized metered dose inhaler
into a connected device: it is then able to record data related to the
inhalations and to assure an optimal management of the treatment
(mastering of the inhalation technique). Equipped with miniaturized
sensors and electronic card, Inspair fits on most MDI mouthpieces on the
market using specific adaptors. The system automatically records
data related to daily inhalations, ensures the right preparation
of the canister (shake before usage), assesses the coordination
of actuation with inhalation (“hand-mouth” coordination) and also provides
with useful guidance throughout the inhalation steps.
Inspair acts on the key levers of the integrated therapeutic education
which lowers hospital admissions and calls to emergency services,
reduces the frequency of the attacks and other symptoms, and improves
the patient’s daily comfort. More than a simple tool for treatment,
Biocorp’s connected device becomes an integral part of it.
Still following its Intellectual Property strategy, providing the
company with a key competitive advantage, Biocorp has deposited a series
of international patents that ensure its full ownership, proof of
anteriority and exclusive rights over the exploitation of Inspair.
Founded in 2004 in Issoire (near
Clermont-Ferrand), France, Biocorp is a French company specializing in
the development and manufacturing of medical devices and innovative drug
delivery systems. It is listed as ‘Innovative Company’ by the French
public investment bank Bpifrance. With over twenty years of experience
and more than 30 manufactured products, Biocorp is a key player in the
industry, providing drug delivery solutions that meet the evolving needs
of patients. Today, Biocorp continues to innovate in the area of medical
plastics, its core business, and to market traditional devices
(alternative to aluminum capsules, syringe and vial administration
systems) that have been an important source of recurring income. Its
solid expertise and capacity to innovate have allowed the company to
develop new Internet-connected products, including: the DataPen, a
reusable smart injection pen that automatically transmits data to a
mobile app, helping patients to manage their treatment; and treatment
management add-ons, which adapt to existing delivery devices and are
compatible with most injection pens in the market. The company has a
team of 44 employees.
Biocorp is listed on Alternext since July
2015 (FR0012788065 – ALCOR).
For more information, please visit: www.biocorp.fr
us on Twitter @BIOCORPSystems
1 Source: http://www.lemonde.fr/sante/article/2016/05/03/quatre-millions-d-asthmatiques-en-france-un-chiffre-sous-estime_4912620_1651302.html#SwIJb5JXKS4Ebi7K.99
Source: French Institute for Research and Documentation in the Economics
of Health (IRDES)
4 Source: COPD French Association
View source version on businesswire.com: http://www.businesswire.com/news/home/20161005005908/en/